Home > Insider Trading > Filing (0001179110-14-009095)

Filing Details

Accession Number:: 0001179110-14-009095
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-23 19:44:12
Reporting Period:: 2014-05-21

Filing Date:: 2014-05-23
Accepted Time:: 2014-05-23 19:44:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	Pharmaceutical Preparations (2834)	263931704

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270734	Deepika Pakianathan	Delphi Ventures, 3000 Sand Hill Rd, Bldg 1, Ste 135 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-05-21	91,754	$26.19	2,174,550	No	4	P	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2014-05-21	896	$26.19	21,233	No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.
Common Stock	Acquisiton	2014-05-22	19,807	$26.09	2,194,357	No	4	P	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2014-05-22	193	$26.09	21,426	No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.
Common Stock	Acquisiton	2014-05-23	1,752	$26.45	2,196,109	No	4	P	Indirect	By Delphi Ventures VIII, L.P.
Common Stock	Acquisiton	2014-05-23	17	$26.45	21,443	No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Delphi Ventures VIII, L.P.
No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.
No	4	P	Indirect	By Delphi Ventures VIII, L.P.
No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.
No	4	P	Indirect	By Delphi Ventures VIII, L.P.
No	4	P	Indirect	By Delphi BioInvestments VIII, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.92 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C ("DMP"), the general partner of each of Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P. (collectively, the "Delphi Funds"). As a managing member of DMP, the Reporting Person shares voting and investment power over the shares held by the Delphi Funds and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such shares held by the Delphi Funds, except to the extent of her proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.98 to $26.25, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.45, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.